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We develop a model of induced innovation where research effort is a function of the death rate, and
thus the potential to reduce deaths in the population.  We also consider potential social consequences
that arise from this form of induced innovation based on differences in disease prevalence across population
subgroups (i.e. race).  Our model yields three empirical predictions.  First, initial death rates and subsequent
research effort should be positively correlated.  Second, research effort should be associated with more
rapid mortality declines.  Third, as a byproduct of targeting the most common conditions in the population
as a whole, induced innovation leads to growth in mortality disparities between minority and majority
groups.  Using information on infant deaths in the U.S. between 1983 and 1998, we find support for
all three empirical predictions.   We estimate that induced innovation predicts about 20 percent of
declines in infant mortality over this period.  At the same time, innovation that occurred in response
to the most common causes of death favored the majority racial group in the U.S., whites.  We estimate
that induced innovation contributed about one third of the rise in the black-white infant mortality ratio






















  Technological change is a source of substantial aggregate welfare improvements.  
Several studies suggest that technological change accounts for up to a third of aggregate 
economic growth (Jorgenson 2000).  Yet overall welfare gains do not imply equal benefit 
for all individuals.  If technological change is biased towards some industries or groups, 
some parts of the population will benefit more than others.   
In this paper, we investigate biased technological change using a particular 
example – medical technology for treating at risk infants.  Infant mortality provides a 
useful setting to learn about induced innovation because the outcome is easy to measure 
(deaths) and disparities in outcomes are so widely noted.  Further, there has been 
enormous technological progress.  In the early 1960s, about 25 of every 1,000 infants 
died before their first birthday, most before leaving the hospital.  Much of this death was 
in premature infants – infants born before normal gestation, and typically low birth 
weight, or under 2500 grams.   
The situation of newborns dying so young created a moral imperative to reduce 
those deaths.  The highly publicized death of John F. Kennedy’s infant son shortly after 
his premature birth attracted further attention to the magnitude of deaths to infants.  
Clinicians treating infants began to innovate, starting what would spur the development 
of neonatal intensive care units (Baker 1996; Anspach 1997).  Grant money followed, 
and physicians and scientists became energized.  Treatment progress was impressive.  In 
the four and a half decades since 1960, mortality for low birth weight babies declined 70 
percent, almost entirely as a result of improved medical care (Cutler and Meara, 2000).   
The first part of our empirical analysis shows the link between humanitarian need 
and technological change.  We look at the role of induced innovation using data on death  
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by cause.  We investigate whether causes of death with higher mortality rates early in the 
time period experienced larger reductions in infant mortality over time.  Our results 
support this prediction.  Every death per 1,000 births attributed to a particular cause in 
1983-85 is associated with a 20 percent greater reduction in mortality from that cause 
over the subsequent 13 years.   
We then go on to examine the impact of these changes on social inequities in 
health.  We focus specifically on the ratio of black to white infant deaths, which 
characterizes the relative rate of progress for blacks compared to whites.  Since there are 
nearly four times as many white than black births, leading causes of death will inherently 
be those which whites suffer from relatively more.  When progress was made on leading 
causes of death, therefore, it benefited white newborns more than black newborns.  Using 
counterfactual simulations, we show that racial gaps in birth weight-specific mortality 
have widened over time as a direct result of the research progress that was made.  As a 
result, medical need has led to improved aggregate outcomes, but with a disproportionate 
share of those benefits accruing to majority groups. 
The paper is structured as follows.  The first section presents a simple model of 
induced innovation in medicine that shows why research would be allocated to more 
common diseases and how induced innovation could increase disparities in health 
outcomes.  The second section describes infant mortality trends in recent decades and 
presents a case study of a particular cause of death, respiratory distress syndrome (RDS).  
Section three presents the data, and section four empirically tests for induced innovation.  
Section five then translates these estimates into the social consequences of induced 
innovation.  The last section concludes.  
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II.   A Model of Induced Innovation  
  In this section, we use a simple framework to explore how the obvious and 
painful suffering of people near death could lead to technological change, and how that 
change might affect different population groups.  For simplicity, we consider the setting 
we employ in our empirical analysis: survival of low birth weight infants. 
A significant body of recent research has considered models of endogenous 
innovation.  In most of these models, innovation is posited to respond to profits – either 
greater demand for some industries (Schmookler, 1966; Romer, 1990; Grossman and 
Helpman, 1991; Aghion and Howitt, 1992; Kremer, 2002; and Acemoglu and Linn, 
2004) or differential factor costs (as in Newell, Jaffee, Stavins, 1999; and Popp, 2002).   
The medical sector is not well characterized by pure profit motives, however.  
Most hospitals are not-for-profit and much innovation is done by independent, university-
based researchers.  We posit an alternative framework in which the humanitarian desire 
to improve health drives innovation.  Lichtenberg (2001) and Bhattacharya and Packalen 
(2008) similarly model the allocation of public spending and innovation in the non-profit 
sector. 
We consider a set of diseases that might result in death, abstracting from quality 
of life.  Let the mortality rate for a particular diagnosis i at a point in time t be denoted di
t.  
We consider two periods, a base period t = 0 and a later period t = 1, where individuals 
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1
, where n is the number of distinct diseases.  
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Medical research on a particular condition will improve survival according to a 
(probabilistically) known innovation possibility function.  We model this as a function 
fi(ri), that converts research between periods 0 and 1 into a survival probability at time 1.  
We assume straightforwardly that fi(0) = 0, fi < 1, fi’ > 0, and fi’’ < 0.  The death rate for 
condition i at time 1 is then di
1 = di
0 · (1 – fi(ri
0)), and the aggregate death rate in period 1 
is  () . ) ( 1
1
0 1 ∑ − ⋅
n
= i
i i i r f d = D
 
Note that this formulation assumes no spillovers across diseases – that is, research 
conducted on one disease affects mortality only for that condition.  We argue below that 
this assumption is conservative in our setting. 
We consider a social planner wishing to maximize social welfare.  This might be 
the National Institutes of Health, which funds a large share of basic biomedical research, 
or university researchers on their own, thinking about valuable projects to explore. The 
social planner wishes to minimize mortality in period 1, with a total research budget fixed 
at R.   
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.            ( 1 )  
The first-order condition is straightforward:  
  di
0 · fi'(ri*) = dn
0 · fn'(rn*), for all i.        ( 2 )  
Equation (2) states that the expected marginal benefit of research should be the 
same across all diseases.   Provided the fi functions are not too different across conditions,  
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this means that more common diseases deserve research that is less productive on the 
margin, and thus get more research funding.
1   
  Disparities in health outcomes will be related to research innovation.  Because 
more medical research is done for more common diseases, the socially optimal allocation 
of research dollars will tilt towards diseases that are relatively more common in larger 
population groups.   
To see this, consider the case where there are two groups, a majority group a and 
a minority group b (in our empirical example, whites and blacks).  Let the initial death 
rates per condition for two groups be 
0
,i a d  and 
0
,i b d  and their respective sums across 
conditions be Da
0 and Db
0.  At time 1, the death rates are given by  
1
,i a d = 
0
,i a d · (1 – fi(ri))    and    
1
,i b d = 
0
,i b d · (1 – fi(ri)), 
and the mortality ratio at each time is given by Db
t/Da





0, which in our model expands to 
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Thus the mortality ratio rises when increases in survival probabilities (fi(ri)) are correlated 
























2   
                                                 
1   In our work, we do not observe differences in the innovation function, so we consider it similar 
across diseases.  Bhattacharya and Packalen (2008) attempt to model this empirically, assuming a structural 
model of research opportunity for pharmaceuticals that declines as drugs get older.     
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  Such a correlation can be present for several reasons.  The difference in the initial 
shares of deaths attributed to a given condition across groups may arise because a 
particular disease is more prevalent in the majority population than in the minority 
population, or more fatal for the majority group.  For example, among infants born 
prematurely, black infants tend to have less severe illness than do white infants along a 
number of dimensions, holding gestation constant (Hulsey et al. 1993; Richardson et al. 
1994; Richardson et al. 1999; Berman et al. 2001).  In particular, at any given gestation, 
black infants are less likely to have RDS, and, on illness severity measures, black infants 
score better than whites even given the presence of a condition like RDS (Hulsey et al. 
1993; Richardson et al. 1994).  Thus, death rates from RDS are greater among whites 
than among blacks, even within narrow birth weight categories.  As a result, research on 
RDS will disproportionately benefit whites over blacks. Thus, if research favors common 
causes of death, we can expect (fi(ri)) to be positively correlated with higher death rates in 
a majority group.  
   In this model, the increasing disparity occurs as a consequence of the differences 
in population sizes, not because deaths are valued differently by the social planner.  To 
see this more formally, consider two diseases, one with a greater prevalence among 
whites and the second with a greater prevalence among blacks.  Let e1
0 be the prevalence 
of disease 1 among whites in the base period, and θe1
0 be the prevalence among blacks, 
where θ<1.  Conversely, let e2
0 be the prevalence of disease 2 among blacks and θe2
0 be 
the prevalence among whites.  To simplify notation, suppose that each case of the disease 
is fatal, so that death rates are equal to prevalence rates.   
                                                                                                                                                 
2 Note that in the model, increases in survival probabilities (fi(ri)) are assumed to be constant for the two 
groups.  
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1 , where Na and Nb 
are the number of white and black births respectively.  Similarly, the mortality rate for 
disease 2 is 
b a
b 2 a 2
N + N




2 .  Combining these mortality rates with equation (2) 
gives a formula for the marginal product of research on each disease in equilibrium: 





























1 1      ( 5 )  
If θ<1 and Na > Nb, the second expression on the right hand side of equation (5) is 
less than 1, and hence the overall expression on the right hand side is less than the ratio of 
disease incidence in the two groups.  As a result, disease 1 should receive relatively 
greater funding than if the populations were the same, with the disparity rising as the 
population disparity rises. 
The induced innovation hypothesis has several predictions, which we test in the 
empirical section of the paper.  First, the theory predicts that initial death rates and 
subsequent research effort should be positively correlated. Second, innovation should be 
associated with more rapid mortality declines.  As a result, induced innovation leads to 
growth in mortality disparities between minority and majority groups.   
 
II.   Background on Infant Mortality and Neonatal Medicine 
  Infant mortality, or death during the first year of life, used to be much more 
common than it is today.  In 1915, for example, infant mortality was 150 babies per 1,000 
born alive.  With improved nutrition and advances in public health, that rate fell to 26 per 
1,000 in mid-century.    
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The latter half of the 20
th century witnessed continued declines in infant mortality.  
Figure 1 demonstrates that white infant mortality rates fell from 26 deaths per 1,000 live 
births in 1950 to 5.7 in 2004.  Black infants experienced higher rates of mortality at every 
point in time, but infant mortality fell dramatically for blacks as well, from 43.9 deaths 
per 1,000 live births in 1950 to 13.8 deaths per 1,000 births in 2004.  The economic value 
of this improvement is immense.  Using the common estimate of $7 million per life, the 
value of reduced mortality is roughly $210,000 per black birth and $140,000 per white 
birth.  With about 3 million black and white births per year in the United States, this 
translates to roughly $550 billion per year.   
A good share of the reduction in infant mortality in the past half century has come 
from reduced mortality of low birth weight infants, consistent with the concentration of 
deaths among babies born low birth weight.  In 2004, nearly 70 percent of infant deaths 
occurred among the 8 percent of babies born weighing under 2500 grams.  Figure 2 
depicts the gain in survival by birth weight.  Mortality for the lightest infants (500-999 
grams) fell from nearly 90 percent in 1960 to 30 percent in 1998.  Mortality among 
infants weighing 1,000 to 1,499 grams fell from 50 percent to below 10 percent.  Over 
half of improved survival for all infants between 1960 and 2005 was a result of lower 
mortality in low birth weight infants.
3 
Unlike early in the century, when improved nutrition and public health were the 
keys to improved survival, advances in medical care were much more important in the 
last few decades.  Low birth weight infants die of many causes, but respiratory-related 
                                                 
3 Compared with the actual infant mortality rate of 6.86 per 1000 live births in 2005, the infant mortality 
rate would have been 14.79 in 2005 based solely on improved rates of survival among low birth weight 
infants.  Compared to the 1960 mortality rate of 25.14, this represents 57 percent of the actual improvement 
in survival from 1960 to 2005.  
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conditions and congenital anomalies are particularly important.  Among the very lightest, 
or Very Low Birth Weight births (< 1500 g), respiratory-related conditions were the most 
common cause of death in 1980.  An infant’s lungs do not develop the capacity to 
transfer oxygen into the blood until about 23 to 25 weeks of gestation, and even after that 
time difficulties breathing are common.  In the 1970s and 1980s, RDS and the related 
bronchopulmonary dysplasia, which often resulted as a consequence of treatment with 
ventilators, were the primary causes of mortality among Very Low Birth Weight infants, 
and an important condition for low birth weight infants.  At that time, RDS caused about 
10,000 deaths per year.  A major part of medical care for premature infants is helping 
them breathe.  Other major causes of infant death include sudden infant death syndrome, 
congenital anomalies (especially heart defects), infections, and pneumonia. 
Starting in the 1960s and continuing today, neonatal intensive care emerged as a 
field of medicine to treat those conditions.  Neonatal intensive care embodies hundreds of 
small innovations often adopted from care for adults, but adapted to very light infants.  
The innovations range from improving the technology for ventilation, improving the 
ability to monitor newborn blood and respiratory function, to the development of 
synthetic surfactant that can be administered to infants with RDS.  These innovations do 
not guarantee survival, but they increase its chances.  Cutler and Meara (2000) show that 
improved care during the neonatal period for critically ill infants collectively accounted 
for essentially all of the reduction in neonatal mortality after 1960.   
Even as overall infant mortality fell from 1950 on, the ratio of black to white 
infant death rates rose.  In 1950, the ratio of black to white infant mortality was about 1.6.  
In the early 1980s, it was just above 2.0.  By the late 1990s, the ratio was about 2.5.  The  
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increase in this ratio has been widely noticed.  The U.S. government’s Healthy People 
2010 initiative has called for the elimination of racial disparities in health outcomes.  Yet 
the most prominent indicator of racial inequality is moving adversely to goals.  As a 
result, there has been a good deal of focus on how to improve black infant outcomes 
(AHRQ 2001; AHRQ 2008; Howell 2008). 
Some of this adverse trend for blacks relative to whites is a greater incidence in 
low birth weight births among blacks.  But that is not the entire story; our calculations 
(described below) indicate that adverse trends in the birth weight distribution account for 
only one-third of the increase in the black-white infant mortality ratio.  The rest comes 
from differential improvements in survival at any given birth weight -- racially-biased 
technological progress.   
 
An Example: Respiratory Distress Syndrome 
To understand the effects we analyze, consider the specific example of RDS.
4  
Somewhere between 24 and 28 weeks of gestation, a healthy, developing fetus begins to 
produce surfactant.  The role of surfactant is to help keep the lung sacs, or alveoli, open.  
Without ample surfactant, the alveoli collapse during breathing, causing damaged cells to 
collect in airways, and impeding breathing ability.  Death is a frequent result.  By 35 
weeks gestation, most babies have developed enough surfactant to maintain appropriate 
surface tension in lung airways.  In the interim between 24 weeks and 35 weeks 
(approximately), infants are at decreasing risk of death from RDS.   
                                                 
4   A review by Clements and Avery (1998) characterized the progress leading to modern day 
treatment for RDS in detail.  
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The first observations about the biological process of RDS were made as early as 
1903.   However, it was not until after 1950 that surfactant was discovered in lung 
extracts and eventually connected to what is now known as RDS.  Between the late 1950s 
and the early 1990s, a wave of government, industry, and academically sponsored 
research helped to uncover the treatments for RDS.  The first scientists experimented in 
uncontrolled settings and reported the use of animal surfactant from rabbits and cows.  
This early research, reported by 1980, spurred other researches to launch controlled 
clinical trials using animal surfactant.  Synthetic surfactant was developed later on, with 
continuing trials to determine the appropriate timing of treatment and optimal delivery of 
the drug.  The effort was immense; an estimated 30,000 infants across North America, 
Europe, and Japan were enrolled in clinical trials of surfactants by 1990.  The results of a 
subset of these, over 35 randomized controlled trials of 6,000 infants, have been reported.  
Surfactant was approved for wide use by the FDA in August, 1990. 
Figure 3 shows the resulting trend in RDS mortality.  To hold constant need, we 
present RDS mortality for two specific weight ranges: 500-999 grams, and 1,000-1,499 
grams.  These ranges correspond to the greatest respiratory impairment.   
Both blacks and whites had high mortality rates from RDS in the early 1980s.  
The rate for whites was about 120 deaths per 1,000 births for the lighter infants, and 50 
deaths per 1,000 births for the heavier ones.  The rate for blacks was high as well, 
although a bit lower in each case.  As noted above, black infants experience faster 
maturation of lungs than white infants (Richardson et al. 1999; Berman et al. 2001). 
Because surfactant was so promising, a large share of very low birth weight 
babies was enrolled in clinical trials of the drug in the 1980s.  Thus, the decline in RDS  
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mortality in the 1980s is likely due to surfactant.  The approval of surfactant in 1990 
coincided with a further immediate decline in death rates and a continuing decline over 
the next few years.  Between 1983 and 1998, RDS-related mortality for black and white 
babies combined fell 63 percent among those weighing 500 to 999 grams, and by 87 
percent among those weighing 1,000 to 1,499 grams.  Because RDS was more important 
for white babies than black babies, however, the reduction in RDS mortality led to 
significantly greater survival improvements for whites than for blacks.  Thus, even with 
equal declines in mortality across racial groups, there was an increase in the racial gap in 
outcomes.  Between 1983 and 1998, we estimate that about 20 percent of the increase in 
the ratio of black to white infant mortality resulted from improvements in RDS survival. 
 
III.   Data 
To understand the sources of innovation in infant medical care, and the 
consequences of those innovations, we use data on mortality by race and cause, and on 
medical innovation.  We describe the sources in turn.   
The mortality data we employ come from cohort linked birth / infant death 
(LBID) files produced by the National Center for Health Statistics (NCHS, various 
years).  These files contain a nearly universal sample of births and infant deaths in the 
United States, formed by compiling data from birth and death certificates.
5  Deaths that 
occur within one year of birth are matched back with their birth certificates to create the 
linked records.  The files are organized by annual, calendar year birth cohorts, so deaths 
                                                 
5   In 1983 and 1984, some states created records for only half of births, randomly selected, but all 
deaths were entered.  Birth records have weights to adjust for the sampling.  
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may be from the same year or the following year as long as they occur within 365 days of 
birth.   
The earliest LBID data is from 1960. However, only published tabulations of 
those data exist, and the published tabulations do not have the detail we need.  The next 
year of linked data are from 1983, and are available in micro data.  We thus use data from 
1983-85 as our early time period.  We pool years to improve death rate estimates for 
relatively rare conditions.  Fortunately, changes in infant mortality were ongoing in this 
time period, and the profile of deaths by cause in 1983-85 is similar to that for 1960.  As 
figure 2 shows, mortality among low birth weight infants roughly halved between 1983 
and 1998.  Changes in the coding of cause of death after 1998 led to substantial 
differences in cause-specific death rates among low birth weight births after that year, so 
our later time period uses data from 1996-98.   
From these records, we use information on birth weight, the mother’s race and 
Hispanic ethnicity, singleton or plurality of birth, and the underlying cause of death.  We 
include births only to black or white mothers, excluding births to Hispanic mothers to 
limit the effect of increasing immigration over time.  We further exclude plural births to 
limit the effect of secular changes in multiple births due to fertility treatment and a 
contemporaneous rise in maternal age, which increases the risk of multiple births 
(Blondel and Kaminski 2002). 
  Summary statistics for the mortality data are shown in Table 1.  In 1983-85, the 
infant mortality rate for whites was 8.2 per 1,000 births and the rate for blacks was 17.1 
per 1,000 births, for a corresponding black-white ratio of 2.09.  Because blacks are a 
smaller share of the population than whites (84 percent of births are for whites, excluding  
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Hispanics), however, there are many more white deaths than black deaths.  Over 70 
percent of infant deaths are among white infants. 
  The next column of the table shows the substantial reduction in infant mortality 
over time.  The infant mortality rate for whites fell by 37 percent between 1983-85 and 
1996-98; the comparable reduction for blacks was 23 percent.  As a result, the black-
white infant mortality ratio rose to 2.4, a 30 percentage point increase.   
  Our model does not address changes in the birth weight distribution over time.  
We thus purge from the increase in the black-white mortality ratio the contribution of 
unequal changes in birth weight by race.  The fourth column of Table 1 shows a 
simulation of infant mortality rates in 1996-98 if the race-specific distribution of births by 
500 gram intervals had not changed over the time period.  In both cases, infant mortality 
rates would be lower, reflecting a trend towards more low birth weight infants over time.  
But the changes are not large.  Relative to the 30 percentage point increase in the 
unadjusted black-white infant mortality ratio, the adjusted increase is 21 percentage 
points.   
  In the final column, we modify the simulation further to give both races the same 
percent reduction in deaths for each cause within 500 gram weight groups.  This 
eliminates changes in mortality ratios that would arise due to differential reductions in 
mortality for a given cause, for example because access to care differs.  The only reason 
mortality changes differ in this scenario is because the causes of death differ for black 
and white babies, and relatively more progress is made on some causes of death.  This 
simulation implies a 12 percentage point increase in the black-white ratio of infant 
mortality.  It is this aspect of rising mortality ratios, the part that arises from induced  
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innovation, that we will explore with the model and empirical analysis that follow. The 
difference between the 21 percentage point growth in black-white mortality ratios and 
this 12 percentage point increase, or 9 percentage points, represents changes that occurred 
because of differential reductions in cause-specific mortality.  That is, for some causes of 
death, the rate at which infant deaths fell was faster for whites than for blacks.   
A faster survival gain for whites may relate to several underlying factors.  If a 
disease manifests itself differently among white versus black infants, then efficacy of 
treatment may vary across races because induced innovation focuses more on the 
majority group, whites.  If differential efficacy of treatments occurs, then we have 
underestimated the role of induced innovation by ignoring this portion of the rising 
mortality ratio, since we have no way to disentangle this from two other potential sources 
of differential survival gains: access and quality of care.  Differences in survival gains 
might also reflect differential access to care, or differential quality of care conditional on 
access.  These latter two explanations do not relate to induced innovation. 
 
Causes of death 
For each infant who dies, the LBID data reports an underlying cause of death.  
We use this to calculate death rates for specific conditions, separately by race.  The 
causes of death are grouped into categories based on an NCHS categorization of the 
International Classification of Diseases -9
th Revision (ICD-9) codes (the 61 Cause 
Recode); the data appendix has details, including a full list of the condition categories.  
After making adjustments to the causes, we identified 69 independent conditions, and one 
residual category.  
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Death rates by leading cause of death are shown in Table 2a.  To highlight the 
role of differing causes within birth weights, we show mortality rates as if blacks and 
whites had the same distribution of births in each weight category.  The 14 conditions 
listed in the table account for half of all infant deaths in 1983-85.  The top three causes, 
Sudden Infant Death Syndrome (SIDS), RDS, and congenital heart anomalies (heart 
defects), stand out in magnitude, accounting for nearly 30 percent of deaths.  SIDS 
primarily occurs outside of the hospital setting and affects children of all birth weights.  
The other causes are predominant in low birth weight babies.  
The ranking of the conditions is different for blacks and whites.  Respiratory 
conditions tend to be a greater cause of death for whites than blacks.  In contrast, issues 
that arise because of conditions at the time of delivery such as birth asphyxia, or 
complications relating to the placenta or umbilical cord are more likely to cause deaths 
among blacks.  For example, RDS is the second most important causes of death for 
whites (accounting for 9.1 percent of deaths), but the third most important cause for 
blacks (accounting for 5.6 percent of deaths).  Among low birth weight infants, death 
rates due to RDS in 1983-85 (14 per 1000) were over 50% higher than they were for 
black infants (9 per 1000), as table 2b shows.  Thus, any advance in RDS led to more 
rapid reductions in infant mortality among whites. 
 
Measures of Innovation 
We construct two measures of innovation related to infant conditions: the number 
of NIH grants associated with each condition, and the number of peer-reviewed journal 
publications associated with each condition.  Each of these has been used as a measure of  
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innovation in past studies.  The grants data come from the Computer Retrieval of 
Information on Scientific Projects (CRISP) database of biomedical research grants, 
maintained by the National Institutes of Health.  Each entry includes a thesaurus of key 
words, allowing us to search for relevant grants.  A complete list of our search terms is 
available from the authors upon request.  In cases when the use of multiple search terms 
returned duplicate grants, we removed duplicates from the final counts.  We created 
counts of grants for two periods, 1975-82 and 1983-98, to capture new innovative effort 
during our study period as well as earlier research that may have produced clinically 
useful results between 1983 and 1998.
6 
The publications data come from the MEDLINE database of medical journal 
articles, maintained by the National Library of Medicine.  This database has an index of 
hierarchical subject headings, so identifying articles that are relevant to a particular cause 
of death can be accomplished by searching on the appropriate headings, when available.  
First, we identified subject headings denoted as “major” topics, and searched on these 
major topics that closely matched causes of death.
7  In some cases, there were no “major” 
topic subject headings matching the cause of death (or category) sufficiently, so we 
searched for terms in the titles and abstracts of articles.  A complete list of our search 
commands is available from the authors upon request.  For all causes, we counted articles 
that were published during the study period (1983 to 1998).   
                                                 
6 We elected to start counting grants in 1975 due to data availability at the start of this study (at that time 
data were not available earlier), and because we felt that eight years offered ample time for grant activity to 
begin to disseminate through various channels.  In practice, our results show little sensitivity to the choice 
of time period, except that earlier grants are somewhat stronger predictors of mortality changes compared 
with later grants. 
7   We identified the appropriate headings by searching the database of subject headings for terms 
from the NCHS categories and ICD-9 entries.    
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For many of the conditions we study, peer-reviewed publications reflect 
innovation that has already occurred, since they tend to summarize evidence from 
completed clinical trials.  In some cases, as in the case of treatments for premature 
infants, multi-site trials may actually affect a large share of the relevant population.  
Thus, our measure of innovation likely captures innovation that occurs just before and 
during our period of study.   
In some cases, categories are too broad to identify a relevant subject category for 
grants or publications (e.g., “viral diseases,” or “remainder of diseases of respiratory 
system”).  In the absence of a subject heading that captured a given condition, we did not 
include that grant or article.  Out of 69 possible categories (not counting the residual 
category), we successfully constructed grants counts for 49 conditions and journal article 
counts for 41 conditions.  The conditions with both measures account for over 85 percent 
of deaths not in the residual category, or 66 percent of all deaths, in the initial period.     
Over the 1983-98 time period, the mean number of grants per condition was 136, with an 
interquartile range of 34 to 156.  Journal articles are more numerous than grants.  The 
average condition had 1,315 journal articles devoted to it over the 1983-98 time period, 
with an interquartile range of 336 to 1,810. 
 
IV.  Testing for Induced Innovation 
In this section, we test the predictions of the induced innovation model.  We start 
with the prediction that initial death rates and subsequent research should be related.  We 
estimate equations of the form: 
ri = α0 + α1 di
0 + εi        ( 6 )   
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Figure 4 shows the relation between initial mortality rates and research 
graphically.  The upper panel shows that conditions with higher mortality rates in 1983-
85 have more journal articles devoted to them in the subsequent 15 years.  The lower 
figure shows that the same is true about the number of NIH grants.  In both cases, a good 
part of the line is defined by conditions with very high mortality rates.  That is not 
necessarily problematic, although we examine the sensitivity to this in our results below. 
The magnitude of these relations, and potential other correlates, are shown in 
Table 3.  The first column shows the relation graphed in figure 4(a).  Each death per 
1,000 births due to a particular cause in 1983-85 is associated with nearly 500 NIH grants 
on that disease from 1983 to 1998.  The second column explores the sensitivity of this 
result to SIDS, RDS, and heart defects.  Without those three conditions, the coefficient 
estimate is still positive, but smaller and not statistically significant.  At least some of our 
results are related to the fact that very big causes of death get more research effort.  Since 
there is no obvious reason to exclude these causes of death from our analysis, our 
subsequent findings include those data. 
The third column shows that each death per 1,000 births is associated with over 
2,700 articles in the 1983-98 time period.  As with the grant data, the coefficient falls and 
is no longer statistically significant when SIDS, RDS, and heart defects are excluded.  As 
the fifth, sixth, and seventh columns show, the initial death rate is proxying for grant 
activity – generally with a lag.  Every additional grant in the 1975-82 time period is 
associated with eight additional articles in the 1983-98 time period.  More recent grants 
have a smaller impact on articles, although this may be a function of the specific timing 
of grants in this interval.  
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The second part of the analysis looks at the impact of initial mortality and 
research on subsequent mortality changes.  The theory predicts that declines in mortality 
should be negatively correlated with higher initial mortality rates, and that this 
relationship should be mediated by research activity.  To look at the relation between 
initial mortality and subsequent mortality changes, we estimate equations of the form: 
  i i i i ε + d β + β = d d
0
1 0
0 1 ) / ( ln       ( 7 )  
Because of the heteroskedasticity induced by very low mortality rates, we express the 
dependent variable in logarithms.  We also weight the regressions by the theoretical 
standard error.
8 
To control for changes in the birth weight distribution over time, we measure both 
initial and final mortality using a constant birth weight distribution, equal to the birth 
weight distribution at baseline in 1983-1985.   
Taken literally, our theoretical model implies β0 = 0; a condition with no deaths 
should have no research, and hence no change in the death rate.  In reality, the constant 
term captures a variety of departures from the model, such as a reduction in overall 
mortality risk over time that results independent of research (due to improved nutrition, 
for example), innovations that affect all conditions, and spillovers in research across 
conditions.  Also, to the extent that research allocation is non-optimal (for example, due 
to political pressure) or the fi are not equal, β1 would be diminished and β0 would differ 
from zero. 
                                                 
8    In particular, we weight the regressions by the inverse of the standard error of the dependent 
variable, the ln change in mortality.  This is calculated using the Delta method and the asymptotic variances 
of the individual mortality rates.  
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Figure 5 shows the relation between initial mortality and the decline in subsequent 
mortality.  There is a negative relationship between the two, again with a large 
component played by SIDS, RDS, and heart defects.  The first column of Table 4 shows 
the corresponding regression coefficient.  Across all 69 conditions, initial mortality is 
negatively and statistically significantly related to mortality changes.  The coefficient on 
initial mortality implies that each additional death per 1,000 births is associated with a 20 
percent greater mortality reduction.  The constant term is negative and implies a 31 
percent reduction in mortality over time.  The relatively large magnitude indicates that 
induced innovation is not the only effect in the data.  As the second column shows, the 
coefficient on initial mortality is actually larger excluding SIDS, RDS, and heart defects, 
but the standard errors are larger as well.  The big causes of death are a large part of our 
story. 
The theory suggests that the relation between initial mortality and subsequent 
mortality declines will be mediated by the amount of research devoted to the disease.  We 
test this in the next columns.  The third column shows the same regression as in column 
(1), but limited to the 41 conditions for which we have journal article data.   The 
coefficient on initial mortality is negative, although smaller than the corresponding 
coefficient in column (1).  The fourth column shows very little relationship between 
articles and changes in mortality.  The coefficient on journal articles is near zero and 
insignificant, and the coefficient on initial mortality remains negative.   
The next two columns show the analogous results using research grants as the 
measure of innovation.  Initial mortality rates are negatively related to changes in 
mortality, and this relationship is mediated by the number of research grants.  Controlling  
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for the number of research grants, the initial mortality rate is positively related to 
subsequent mortality changes, although not statistically significantly so. 
Grants and research articles are both noisy measures of innovation.  Assuming the 
errors in each are uncorrelated, we can use one to instrument for the other and obtain 
more efficient estimates.  The last column of the table instruments for journal articles 
with the number of research grants.
9  The coefficient on research articles is now large and 
negative, and the coefficient on initial mortality is positive.  The constant is much lower 
as well; more of the results are explained by the number of journal articles related to the 
condition.   
The results in Table 4 permit two estimates of the magnitude of induced 
innovation.  One estimate comes from the constant term.  The difference between the 
average rate of mortality reduction and the constant term in equation (7) indicates the 
average mortality reduction due to induced innovation.  The second measure is the 
change in predicted final death rates attributable to the relation between initial mortality 
and subsequent mortality.  Because of the non-linear model,
10 the first estimate 
understates the inducement effect, while the second overstates it.   
  The constant term in the first column of Table 4 implies a decline of 31 percent in 
mortality ( i.e. -.31 = e
-.374-1) compared with the total reduction in the death rate of 37 
percent.  This suggests that about 6 percent, or one-sixth of the actual improvement in 
mortality is due to induced innovation.  The contribution of induced innovation implied 
by the constant term in column 7, the instrumental variables regression that includes 
                                                 
9   The F-statistic on the instrument is 4.43.  
10   In a linear model, these would be the same, but our model is not linear.  The regression equation 
implies E[di
1] = di
0 exp(β0) exp(β1 di
0), so the relative change di
1/ di
0 – 1 equals exp(β0) exp(β1 di
0) – 1.  The 
two measures of induced innovation are thus D
1/D
0 – [exp(β0) – 1], the impact calculated based on the 
constant term, and E[exp(β1 di
0)] – 1, the impact of the slope coefficient.    
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research articles devoted to the condition, is even larger.  Using the estimate of β1 to 
calculate predicted mortality, in contrast, generates a 7.5 percent decline in mortality (i.e. 
E[exp(β1 di
1)]-1), about one-fifth of the actual change.
11  In column 7, using the implied 
change in mortality from the coefficient on research articles, the magnitude of the role for 
induced innovation rises to two thirds of the change.
12  Conservatively choosing 
estimates that are closer to our lower bound, we estimate that about one fifth of the 
reduction in infant mortality over time is a result of induced innovation. 
 
The role of competing risks 
One potential concern about our estimates is the possibility of competing risks.  If 
vulnerable infants saved from one disease are still likely to die of another, decreased 
mortality for one cause of death will not result in as great a reduction in total mortality.  
Alternatively, if research in one disease leads to progress in another, we will understate 
the impact of research on improved outcomes.  However, infants differ from adults in the 
sense that, unlike older adults who are at risk of multiple conditions (hypertension, high 
cholesterol, and diabetes are all related to obesity, for example), infants saved from one 
condition are much less likely to develop other conditions.  In contrast to older adults, 
infants face lower risks of disease incidence as they age, mitigating the disease risk 
problem. 
To test for competing risks though, we return to the RDS example.   RDS is 
important both because of its contribution to the overall evaluation and because 
respiratory distress is so central to infant mortality.  We take advantage of the time series 
                                                 
11  For this estimate, the death rate for the residual category was held constant. 
12   For this estimate, the death rates for all categories without publications data were held constant.  
The implied change in mortality is a 24 percent decline.  
  25
variation to look for competing risks.  If a substantial portion of infants in low birth 
weight groups who died from RDS were at risk from other diseases as well, we would 
expect years with large drops in the RDS death rate to have smaller reductions in deaths 
from other causes.   
Figure 6 shows annual mortality change for RDS and non-RDS causes among 
births 1000-1499 g.  The results are, if anything, the opposite of the competing risk 
explanation.  In years where RDS mortality fell most – especially 1990, the year of 
widespread diffusion of surfactant – non-RDS mortality fell as well; the correlation 
between mortality changes for RDS and all other causes is 0.34.  These results suggest no 
issue of competing risks.  If anything, it appears that as a major cause of death like RDS 
falls, the innovations that contribute to this fall may reduce deaths from other causes as 
well.  One example of this would be bronchopulmonary dysplasia, a condition related to 
extended periods of mechanical ventilation in premature infants.  With the advent of 
surfactant, time on ventilation fell, thus reducing the incidence of bronchopulmonary 
dysplasia (Soll 1998).  Other NICU technologies developed in the treatment of infants 
with RDS could also benefit infants with unrelated conditions.  So, for example, 
improved ventilation techniques developed in response to the wave of RDS infants, might 
also benefit other infants on ventilators.  To the extent that such spillovers exist, our 
estimates of induced innovation yield a lower bound, since they only capture the 
differential mortality reductions that occur across causes of death receiving more research 
effort, and not any potential spillover from induced research effort.   
 
Is Innovation Race Neutral?  
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In our model, medical innovation is race-neutral: doctors and research funders 
seek to reduce the major causes of death, whether they affect blacks or whites.  This may 
not be right, however.  For example, research might be tilted toward conditions that 
whites suffer from, ignoring conditions that are common among blacks.   
One way to test this is to differentiate black and white deaths in the equation for 
subsequent mortality changes.  Consider equation (8), an expanded version of equation 
(7): 





0 1 ) / ( ln       ( 8 )  
where dw and db refer to race-specific deaths as a share of all births.  Thus, dw and db are 
not standard death rates since the race-specific number of deaths are divided by the sum 
of black and white births.  One can thus view dw as capturing the death rate from the 
bundle of causes that kill white infants and db as capturing the death rate from the bundle 
of causes that kill blacks.  A theory of racially biased innovation suggests that black 
deaths should count less than white deaths, i.e.,  | β | < | β | 1 2 .   
Table 5 shows results of regressions separating black and white deaths.  The first 
three columns present results for the impact of initial mortality on subsequent changes in 
mortality.  Independently, black deaths count more than white deaths for subsequent 
mortality changes (column 1 versus column 2), although the standard errors on each are 
large.  The regression has difficulty determining the relative weight to put on the two 
when included in the regression jointly (column 3), but the coefficient on black deaths is 
negative while the coefficient on white deaths is positive.  However these coefficients are 
not statistically different from each other.  
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The next columns show the relation between race-specific initial mortality and the 
number of journal articles and NIH grants.  When included together, white deaths are 
more associated with journal articles than are black deaths, but black deaths are more 
associated with NIH grants.  In these regressions the coefficients are statistically 
different, but their magnitudes suggest a co-linearity problem.  Overall, we find no 
consistent pattern of race-based bias in the innovative process. 
 
  Induced Innovation and Social Inequality 
As shown in our model, induced innovation can have an unintended consequence 
on disparities in health outcomes.  In the model, greater gains in survival occur for causes 
of death that are relatively more common among the majority group.  Thus, the overall 
disparity of health outcomes widens. As discussed in section II, this result arises 
mechanically when the difference in initial death rates across races (majority – minority) 
are positively correlated with survival gains. We test for evidence of this positive 
correlation empirically, by correlating changes in condition-specific death rates to the 
difference in initial shares of death for majority and minority groups.  The correlation of 
0.08 is indeed positive and statistically significant.
13 
The overall impact of this correlation on subsequent inequality changes is shown 
in Table 1.  The last column of the table shows the simulated mortality rates if mortality 
for each cause declined at the same rate for whites and blacks.
14  In this scenario, the 
black-white ratio would change only because white and black babies die of differing 
causes.  As the table shows, the black-white infant mortality ratio still rises by 12 
                                                 
13   Here we control for birth weight by calculating death rates and survival gains within 500-gram 
intervals and then taking a weighted average based on the number of births in each interval. 
14   As in the preceding column, the analysis is conditional on birth weight.   
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percentage points in this scenario.  Thus, about one-third of the increase in the black-
white mortality disparity, (.12/.30), is a result of induced innovation.  Another one-third, 
(.21-.12)/.30, results from the differentially greater reduction in mortality for whites 
relative to blacks within causes.  The remaining one-third, (.30-.21)/.30, is a result of 
differential growth of low birth weight babies among blacks.  Notably, the magnitude of 
rising black-white mortality ratio is comparable to that of the role of induced innovation 
in mortality reductions documented earlier.  In other words, black-white infant mortality 
ratios in the US are responsive to induced innovation, growing with induced 
improvements in survival for infants. 
 
A Falsification Exercise: Education-Based Disparities 
One concern about our findings is that we may be measuring the impact of being 
in an economically disadvantaged group, not necessarily a minority population group.  It 
may be that the economically disadvantaged are doing worse over time, regardless of 
whether they are majority or minority groups.  Since blacks are both a population 
minority and economically disadvantaged, we cannot completely differentiate between 
these theories with our data. 
We test this using data on deaths by maternal education, restricting the sample to 
non-Hispanic whites.  Women with some college education represent a minority of births 
(40 percent), but are better off economically.  Thus, if the effect we find is a result of 
economic disadvantage, babies of women with some college should fare better over time 
than babies of women who never attended college.  If the result is due to population size, 
babies of women who attended college should fare no better than babies of less educated  
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women. Table 6 displays numbers similar to those in table 1, but dividing mothers into 
groups based on college attendance.  As the second column of the table shows, women 
who never attended college have a 53 percent higher mortality rate in 1983-85 than 
women who attended some college. That ratio increased to 88 percent in 1996-98.   
About one-third of that increase is a result of adverse trends in the birth weight 
distribution for women who did not attend college relative to women who did.  Our 
model does not explain such effects.  The entirety of the remainder is a result of more 
rapid declines in mortality within cause for women with some college education.  Indeed, 
as the last column shows, there is no increase in the mortality ratio, or if anything a slight 
decrease, when mortality reductions by cause are assumed to be the same.  Thus, our 
results do not suggest that the causes of death predominant among the economically 
advantaged are declining by more than the causes among the economically 
disadvantaged.  Indeed, the two seem about the same.   
The reason why women with some college education benefitted more from 
progress within causes of death than women without any college education is not clear.  It 
may reflect differences in access to care or the quality of that care, which we do not 
explore.  Overall, however, these results support the conclusion that it is induced 
innovation resulting from minority status itself that leads to less rapid mortality declines 
for blacks, and hence lagging health outcomes. 
  
VII. CONCLUSIONS 
  The dynamics of the medical sector have been a subject of much debate.  Most of 
medical care cost increases are a result of technological progress (Newhouse, 1992), and  
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some studies suggest that health benefits emanate from the same source (Cutler, 2004; 
Cutler, Rosen, and Vijan 2006).   
For at least the last two decades, economists have speculated about the underlying 
source of these technological innovations (Weisbrod, 1991).  The idea that progress is a 
result of perceived need has been common in the literature, although not tested to any 
great extent.  We test the importance of induced innovation by considering care for a 
group that is particularly needy: low birth weight infants.   
We reach two primary conclusions.  First, there is a strong impact of induced 
innovation on technological change.  Disease conditions with higher initial mortality rates 
had more grant effort devoted to them, saw more journal articles about them, and 
experienced a greater reduction in subsequent mortality.  Induced innovation explains 
about 20 percent of the reduction in mortality over time.   
But endogenous technology also benefits majority groups over minority groups.  
Majority groups are of necessity a larger share of total deaths than are minority groups.  
Thus, conditions that affect them more will receive more research attention.  Our results 
show that this leads to a significant increase in the disparity between blacks and whites as 
innovation allows premature white newborns to “catch up” to their black counterparts, 
who, for a given gestation and birth weight, tend to have better health.   
Our results do not arise because medical research is racially biased; our best 
estimates suggest that it is not.  Rather, growing disparities result from the seemingly 
benign tendency of ‘treating what we see’.   If we want disparities to fall over time, our 
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Cause of Death Data 
We start with cause of death as identified on ICD-9 forms and tabulated by the 
National Center for Health Statistics.  We then modify this in several ways.  First, we 
formed 10 additional categories by breaking apart two NCHS categories that grouped 
together distinct conditions with over 100 deaths in 1983-85: 770.xx and codes 775.2-
775.9.  We also formed five categories by identifying conditions within the NCHS 
residual group with over 250 deaths in this period, based on ICD-9, 3-digit codes.  In 
addition, we moved four of the NCHS categories into a residual category because they do 
not identify a specific condition, but are rather residual catchall categories (e.g., 
“...unspecified,” or “all other”).   
Specifically, our modifications from the NCHS 61 Cause Recode were: the 
category for “other respiratory conditions of newborn” (ICD-9 code 770) was subdivided 
into congenital pneumonia (770.0), massive aspiration syndrome (770.1), interstitial 
emphysema and related conditions (770.2), pulmonary hemorrhage (770.3), primary 
atelectasis (770.4), other and unspecified atelectasis (770.5), and chronic respiratory 
disease arising in the perinatal period (Bronchopulmonary dysplasia, Wilson-Mikity 
syndrome) (770.7); “all other and ill-defined conditions originating in the perinatal 
period” (codes 775.2-775.9, and 776.1-779) was subdivided into disseminated 
intravascular coagulation in newborn (776.2), necrotizing enterocolitis in fetus or 
newborn (777.5), and hydrops fetalis not due to isoimmunization (778.0); and categories 
were created for disorders of fluid, electrolyte, and acid-base balance (276),  
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cardiomyopathy (425), primary pulmonary hypertension (416.0), cardiac arrest (427.5), 
and renal failure, unspecified (586).  The final 69 categories are shown in Table A1. 
 
Table A1. Cause of Death Categories 
 
   Articles* NIH  Grants* 
ICD-9 Codes  Condition(s)  1983-98  1983-98  1975-82 
001-007, 010-032, 
034-035, 037,  
039-041, 042-044, 
080-088, 091-139 
Remainder of infectious and parasitic diseases  a  a  a 
008-009  Certain intestinal infections  b  172  38 
033 Whooping  cough  b  113  17 
036 Meningococcal  infection  b  b  b 
038 Septicemia  2466  160  94 
045-079 Viral  diseases  a  a  a 
090 Congenital  syphilis  b  23  3 
140-208  Malignant neoplasms, including neoplasms of lymphatic 
and hematopoietic tissues 
a a a 
210-239  Benign neoplasms, carcinoma in situ, and neoplasms of 
uncertain behavior and of unspecified nature 
a a a 
254  Diseases of thymus gland  b  b  b 
276  Disorders of fluid, electrolyte, and acid-base balance  1640  145  62 
277 Cystic  fibrosis  b  224  158 
280-289  Diseases of blood and blood-forming organs  3689  30  8 
320-322 Meningitis  1630  223  48 
323-389  Other diseases of nervous system and sense organs  a  a  a 
416 Primary  pulmonary  hypertension  336  277  54 
425 Cardiomyopathy  924  17  0 
427.5 Cardiac  arrest  287  77  23 
460-465  Acute upper respiratory infections  a  a  a 
466, 490-491  Bronchitis and bronchiolitis  694  186  109 
480-486 Pneumonia  1810  351  107 
487 Influenza  b  156  61 
470-478, 492-519  Remainder of diseases of respiratory system  a  a  a 
520-534, 536-543, 
562-579 
Remainder of diseases of digestive system  a  a  a 
535, 555-558  Gastritis, duodenitis, and noninfective enteritis and 
colitis 
b 0 0 
550-553, 560  Hernia of abdominal cavity and intestinal obstruction 
without mention of hernia 
b b b 
586 Renal  failure,  unspecified  1088  120  68 
740  Anencephalus and similar anomalies  681  31  52 
741 Spina  bifida  777  153  69 
742.3 Congenital  hydrocephalus  1301  88  60  
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   Articles* NIH  Grants* 
ICD-9 Codes  Condition(s)  1983-98  1983-98  1975-82 
742.0-742.2, 
742.4-742.9, 743 
Other congenital anomalies of central nervous system 
and eye 
b 52 0 
745-746  Congenital anomalies of heart  8334  364  375 
747  Other congenital anomalies of circulatory system  2525  147  61 
748  Congenital anomalies of respiratory system  1137  64  5 
749-751  Congenital anomalies of digestive system  2717  27  3 
752-753  Congenital anomalies of genitourinary system  980  8  0 
754-756  Congenital anomalies of musculoskeletal system  2047  34  12 
758 Down's  syndrome  1242  153  156 
758.1-758.9  Other chromosomal anomalies  474  74  1 
760  Newborn affected by maternal conditions which may be 
unrelated to present pregnancy 
b b b 
761  Newborn affected by maternal complications of 
pregnancy 
1144 119  25 
762  Newborn affected by complications of placenta, cord, 
and membranes 
419 87  3 
763  Newborn affected by other complications of labor and 
delivery 
b 34 0 
764  Slow fetal growth and fetal malnutrition  b  b  b 
767 Birth  trauma  1815  74  47 
768.2-768.4  Fetal distress in liveborn infant  289  101  38 
768.5-768.9 Birth  asphyxia  1161  19  1 
769  Respiratory distress syndrome  2803  776  509 
770 Congenital  pneumonia  26  3  3 
770.1  Massive aspiration syndrome  256  3  7 
770.2  Interstitial emphysema and related conditions  319  42  12 
770.3 Pulmonary  hemorrhage  86  37  2 
770.4 Primary  atelectasis  73  37  13 
770.5  Other and unspecified atelectasis  b  b  b 
770.7  Chronic respiratory disease arising in the perinatal 
period (Bronchopulmonary dysplasia, Wilson-Mikity 
syndrome) 
879 621 29 
771  Infections specific to the perinatal period  1162  125  37 
772 Neonatal  hemorrhage  825  150  54 
773-774  Hemolytic disease of newborn, due to isoimmunization, 
and other perinatal jaundice 
2287 55  54 
775.0-775.1  Syndrome of "infant of a diabetic mother" and neonatal 
diabetes mellitus 
b b b 
776  Hemorrhagic disease of newborn  153  34  20 
776.2  Disseminated intravascular coagulation in newborn  106  23  10 
777.5  Necrotizing enterocolitis in fetus or newborn  624  163  28 
778  Hydrops fetalis not due to isoimmunization  1  2  4 
798  Sudden infant death syndrome  2703  673  387 
E911-E912  Inhalation and ingestion of food or other object causing 
obstruction of respiratory tract or suffocation 
c c c 
E913  Accidental mechanical suffocation  c  c  c  
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   Articles* NIH  Grants* 
ICD-9 Codes  Condition(s)  1983-98  1983-98  1975-82 
E800-E910,  
E914-E949 
Other accidental causes and adverse effects  c  c  c 
E967  Child battering and other maltreatment  c  c  c 
E960-E966,  
E968-E969 
Other homicide  c  c  c 
* Data are not available for all categories.  See the discussion on page 19 for further 
information.  Specific reasons for the absence of data are as follows: 
a. Overly broad category. 
b. Lack of appropriately targeted search terms.  In some cases, in the MEDLINE 
database, we were unable to effectively restrict searches to infant conditions despite the 
presence of an “infant” qualifier. 

































































































Figure 2: Infant Mortality by Birth Weight, 1960, 1983, and 1998
1960 1983 1998
 
Note: Data for 1960 do not present all birth weights.  Infant mortality rate for births 




Figure 3: The RDS Example 




















































































































































Figure 4: Relationship between initial mortality rate and research effort 








Panel B: Number of journal articles, 1983-98











































































Holding birth weight constant 
and same change in cause 
specific mortality rates
White 84% 8.2 5.2 5.0 5.0
Black 16% 17.1 12.4 11.4 11.0
Black/White 2.09 2.40 2.30 2.21
Change in ratio 0.30 0.21 0.12
1996-98
Table 1: Actual and Simulated Change in Racial Disparity
Note: Data are based on the linked birth-death infant data.  Deaths are per 1,000 births.  In the 1996-98 
columns, the second column is a simulation showing changes in infant mortality if the birthweight 
distribution were the same in that time period as in the 1983-85 time period, separately by race.  The 
third column includes that assumption and also simulates the same change in infant mortality rates by 







Cause of death (ICD-9) All races Rank Share  Whites Rank Share Blacks Rank Share
Sudden infant death syndrome 1.42 1 15% 1.29 1 13% 1.95 1 18%
Respiratory distress syndrome (RDS) 0.78 2 8% 0.89 2 9% 0.60 3 6%
Congenital anomalies of heart 0.68 3 7% 0.71 3 7% 0.61 2 6%
Congenital anomalies of respiratory system 0.26 4 3% 0.30 4 3% 0.17 9 2%
Birth asphyxia 0.23 5 2% 0.22 9 2% 0.29 4 3%
Infections specific to the perinatal period 0.23 6 2% 0.24 6 2% 0.23 7 2%
Newborn affected by complications of 
placenta, cord, and membrane 0.22 7 2% 0.26 5 3% 0.19 8 2%
Other congenital anomalies of circulatory 
system 0.21 8 2% 0.20 11 2% 0.27 6 3%
Other chromosomal anomalies 0.19 9 2% 0.23 7 2% 0.11 12 1%
Congenital anomalies of musculoskeletal 
system 0.18 10 2% 0.21 10 2% 0.11 11 1%
Pneumonia 0.18 11 2% 0.15 14 2% 0.28 5 3%
Anencephalus and similar anomalies 0.17 12 2% 0.23 8 2% 0.06 14 1%
Newborn affected by maternal complications 
of pregnancy 0.16 13 2% 0.20 12 2% 0.12 10 1%
Congenital anomalies of genitourinary  0.14 14 1% 0.17 13 2% 0.07 13 1%
All other causes 4.72 --- 48% 4.50 --- 46% 5.74 --- 53%
Table 2b: Leading 5 causes of death among infants born under 2500 grams, 1983-85
Cause of death (ICD-9) All races Rank Whites Rank Blacks Rank
Respiratory distress syndrome (RDS) 12.40 1 14.35 1 9.17 1
Suddent infant death (SIDS) 4.24 2 3.70 2 5.27 2
Newborn affected by complications of 
placenta, cord, and membrane 2.97 3 3.69 3 2.00 5
Congenital anomalies of respiratory system 2.80 4 3.55 4 1.50 9
Infections specific to the perinatal period 2.67 5 2.82 6 2.38 3
Note: Sample restricted to singleton births that are non-Hispanic.  Deaths are per 1,000 births and are 
adjusted to a common birth weight distribution.
All Births
Note: Sample restricted to singleton births that are non-Hispanic.  Deaths are per 1,000 births and are adjusted to a 
common birth weight distribution.





Independent Variable (1) (2) (3) (4) (5) (6) (7)
Initial mortality 488 135 2748 984 2456 -77 251
  per 1,000 births (73) (222) (797) (1923) (1142) (1222) (1220)
Grants (83-98) --- --- --- --- 0.59 --- -2.68
(1.63) (1.76)








defects All All All
N4 9 4 6 4 1 3 8 4 1 4 1 4 1
R
2 0.484 0.008 0.234 0.007 0.236 0.371 0.409
Journal Articles (1983-98)
Note: Each column is a separate regression. Standard errors are shown in ()s. Initial mortality is 
mortality in 1983-85 for singleton, non-Hispanic births.










IV model       
grants and 
articles
Independent Variable (1) (2) (3) (4) (5) (6) (7)
Initial mortality -0.222 -0.715 -0.146 -0.149 -0.168 0.374 0.243
  per 1,000 births (0.096) (0.726) (0.116) (0.127) (0.107) (0.205) (0.315)
Grants (75-98) --- --- --- --- --- -0.070 ---
(100s) (0.023)
Articles (83-98) --- --- --- 0.002 --- --- -0.226
(1000s) (0.028) (0.144)
Constant -0.374 -0.285 -0.457 -0.460 -0.432 -0.373 -0.117
(0.067) (0.112) (0.088) (0.098) (0.080) (0.076) (0.261)
N6 9 6 6 4 1 4 1 4 9 4 9 4 1
R
2 0.074 0.015 0.039 0.039 0.050 0.207 NA
Each column is a separate regression. Birthweight distribution is held constant using 500 gram intervals. All regressions 
are weighted by 1/SE( ln-chg ). The last column instruments for journal articles with the number of research grants.
Table 4: Regressions of Decline in Infant Death Rate, Initial Mortality, & Research Effort





Independent variable (1) (2) (3) (1) (2) (3) (4) (5) (6)
Black deaths -0.837 --- -2.515 8089 --- -28672 1856 --- 2999
  per 1,000 births (0.335) (1.650) (3018) (9660) (251) (953)
  (both races)
White deaths --- -0.298 0.682 --- 3989 14484 --- 648 -449
  per 1,000 births (0.134) (0.657) (1071) (3668) (103) (361)
  (both races)
F test for equal --- --- 1.94 --- --- 10.64 --- --- 6.98
  coefficients [0.169] [0.002] [0.011]
N 6 96 96 9 4 14 14 1 4 94 94 9
R
2 0.085 0.068 0.100 0.156 0.262 0.401 0.537 0.455 0.552
Table 5: Testing for Race-Biased Innovation
Note: Each column is a separate regression.  Standard errors in ()s and p-values in []s.  In columns 1-3, 
the regression are weighted by 1/SE( ln-chg ) and the birthweight distribution is held constant using 
500 gram intervals.



















constant and same 
change in cause-
specific mortality rates
No College 60% 9.5 5.9 5.7 4.9
College attendee 40% 6.2 3.2 3.3 3.3
Ratio (No college:college) 1.53 1.88 1.73 1.49
Change in ratio 0.35 0.21 -0.03
Table 6: Actual and Simulated Change in Educational Disparity
1983-85 1996-98
Note: Data are based on the linked birth-death infant data for white births.  Deaths are per 1,000 
births.  In the 1996-98 columns, the second column is a simulation showing changes in infant 
mortality if the birthweight distribution were the same in that time period as in the 1983-85 time 
period, separately by education group.  The third column includes that assumption and also 
simulates the same change in infant mortality rates by cause for both groups.  The change is 
assumed to be the rate observed for the high education group.  